PTHrP is detected in about 70% of breast cancer‐derived bone metastases, and is elevated in more than 60% of breast cancer primary tumors.(59) This sets PTHrP as a “seed” factor that can be targeted in addition to the “soil” to potentially enhance therapeutic efficacy in patients. The gene discussed is PTHLH; the disease is breast carcinoma.